deucravacitinib

Details

Files
Generic Name:
deucravacitinib
Project Status:
Complete
Therapeutic Area:
Psoriasis, moderate to severe plaque
Manufacturer:
Bristol-Myers Squibb Company
Brand Name:
Sotyktu
Project Line:
Reimbursement Review
Project Number:
SR0756-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
The treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
The treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Recommendation Type:
Do not reimburse
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open29-Aug-22
Call for patient/clinician input closed24-Oct-22
Clarification:

- Patient input submission received from the Canadian Psoriasis Network (CPN) and Canadian Association of Psoriasis Patients (CAPP)

Submission received27-Sep-22
Submission accepted12-Oct-22
Review initiated13-Oct-22
Draft CADTH review report(s) provided to sponsor for comment03-Jan-23
Deadline for sponsors comments12-Jan-23
CADTH review report(s) and responses to comments provided to sponsor09-Feb-23
Expert committee meeting (initial)22-Feb-23
Draft recommendation issued to sponsor07-Mar-23
Draft recommendation posted for stakeholder feedback16-Mar-23
End of feedback period31-Mar-23
Clarification:

- Reconsideration: major revisions requested by sponsor

Expert committee meeting26-Jul-23
Final recommendation issued to sponsor and drug plans
Final recommendation posted24-Aug-23
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)22-Aug-23
CADTH review report(s) posted25-Oct-23